NDC 0574-0240 Repaglinide


NDC Product Code 0574-0240

NDC CODE: 0574-0240

Proprietary Name: Repaglinide What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Repaglinide What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • Repaglinide is used alone or with other medications to control high blood sugar along with a proper diet and exercise program. It is used in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. It works by stimulating the body to produce more insulin. Insulin is a natural substance that allows the body to properly use sugar from the diet.

Product Characteristics

WHITE (C48325)
Shape: ROUND (C48348)
6 MM
Score: 1

NDC Code Structure

  • 0574 - Paddock Laboratories, Llc

NDC 0574-0240-01

Package Description: 100 TABLET in 1 BOTTLE

Price per Unit: $0.14659 per EA

NDC Product Information

Repaglinide with NDC 0574-0240 is a a human prescription drug product labeled by Paddock Laboratories, Llc. The generic name of Repaglinide is repaglinide. The product's dosage form is tablet and is administered via oral form. The RxNorm Crosswalk for this NDC code indicates multiple RxCUI concepts are associated to this product: 200256, 200257 and 200258.

Dosage Form: Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Repaglinide Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.


Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Glinide - [EPC] (Established Pharmacologic Class)
  • Potassium Channel Antagonists - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Paddock Laboratories, Llc
Labeler Code: 0574
FDA Application Number: ANDA201189 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 08-09-2013 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients


Repaglinide is pronounced as (re pag' lin ide)

Why is repaglinide medication prescribed?
Repaglinide is used to treat type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in the blood). ...
[Read More]

* Please review the disclaimer below.

Repaglinide Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitation of Use:Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

The recommended starting dose for patients whose HbA1c is less than 8% is 0.5 mg orally before each meal. For patients whose HbA1c is 8% or greater the starting dose is 1 or 2 mg orally before each meal.The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment.Instruct patients to take repaglinide tablets within 30 minutes before meals. Repaglinide tablets may be dosed 2, 3, or 4 times a day in response to changes in the patient’s meal pattern.In patients who skip meals, instruct patients to skip the scheduled dose of repaglinide tablets to reduce the risk of hypoglycemia. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced [see Warnings and Precautions (5.1)].

2.2 Patients With Severe Renal Impairment

In patients with severe renal impairment (CrCl = 20 – 40 mL/min) initiate repaglinide tablets 0.5 mg orally before each meal. Gradually titrate the dose, if needed to achieve glycemic control.

2.3 Dose Modifications For Drug Interactions

Dosage adjustments are recommended in patients taking concomitant strong CYP3A4 or CYP2C8 inhibitors or strong CYP3A4 or CYP2C8 inducers [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].Concomitant use with gemfibrozil is contraindicated [see Contraindications (4)].Avoid concomitant use of repaglinide tablets with clopidogrel. If concomitant use can not be avoided, initiate repaglinide tablets at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].Do not exceed a total daily dose of 6 mg of repaglinide tablets in patients receiving cyclosporine [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].

3 Dosage Forms And Strengths

  • •0.05 mg tablets (white, round tablets with beveled edges on both sides, debossed with “P240” on one side) •1 mg tablets (yellow, round tablets with beveled edges on both sides, debossed with “P241” on one side) •2 mg tablets (pink, round tablets with beveled edges on both sides, debossed with “P242” on one side)

4 Contraindications

  • Repaglinide tablets are contraindicated in patients with: •Concomitant use of gemfibrozil [see Drug Interactions (7.1)] •Known hypersensitivity to repaglinide or any inactive ingredients

5.1 Hypoglycemia

All glinides, including repaglinide tablets, can cause hypoglycemia [see Adverse Reactions (6.1)]. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see Drug Interactions (7)], or in patients who experience recurrent hypoglycemia.Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content), changes in level of physical activity, changes to co-administered medication [see Drug Interactions (7)], and concomitant use with other antidiabetic agents. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use in Specific Populations (8.6, 8.7)].Patients should administer repaglinide tablets before meals and be instructed to skip the dose of repaglinide tablets if a meal is skipped. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced [see Dosage and Administration (2.1)]. Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.

5.2 Serious Cardiovascular Adverse Reactions With Concomitant Use With Nph-Insulin

Across seven controlled trials, there were six serious adverse events of myocardial ischemia in patients treated with repaglinide tablets plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study [See Adverse Reactions (6.1)]. Repaglinide tablets are not indicated for use in combination with NPH-insulin.

5.3 Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with repaglinide tablets.

6 Adverse Reactions

The following serious adverse reaction is also described elsewhere in the labeling:Hypoglycemia [See Adverse Reactions (5.1)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.Repaglinide tablets have been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 diabetes have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received repaglinide tablets in one of five 1-year, active-controlled trials. Over one year, 13% of repaglinide tablets patients were discontinued due to adverse reactions. The most common adverse reactions leading to withdrawal were hyperglycemia, hypoglycemia, and related symptoms.Table 1 lists the common adverse reactions for repaglinide tablets patients compared to placebo in trials 12 to 24 weeks duration.Table 1: Adverse Reactions (%) occurring ≥ 2% in Repaglinide Tablets Treated Patients from Pool of 12 to 24 Week Placebo Controlled Trials*Repaglinide TabletsN=352PlaceboN=108Upper Respiratory Infection168Headache1110Sinusitis62Arthralgia63Nausea55Diarrhea52Back Pain54Rhinitis33Constipation32Vomiting33Paresthesia33Chest pain31Bronchitis21Dyspepsia22Urinary tract infection21Tooth disorder20Allergy20*See trial descriptions in Clinical Trials (14)HypoglycemiaIn clinical trials with repaglinide tablets, hypoglycemia is the most commonly observed adverse reaction. Mild or moderate hypoglycemia occurred in 31% of repaglinide tablet treated patients and 7% of placebo treated patients [see Warnings and Precautions (5.1]).Hypoglycemia was reported in 16% of 1228 repaglinide tablet patients, 20% of 417 glyburide patients, and 19% of 81 glipizide patients in 1- year controlled trials. Of repaglinide tablet -treated patients with symptomatic hypoglycemia, none developed coma or required hospitalization.In a 24-week placebo controlled trial, patients who were naïve to oral hypoglycemic agent therapy and patients with a HbA1c below 8% at baseline had a higher frequency of hypoglycemia.Weight GainThere was no average gain in body weight when patients previously treated with oral hypoglycemic agents were switched to repaglinide tablets. The average weight gain in patients treated with repaglinide tablets and not previously treated with sulfonylurea drugs was 3.3%.Cardiovascular EventsThe incidence of total serious cardiovascular adverse events, including ischemia, was higher for repaglinide tablets (51/1228 or 4%) than for sulfonylurea drugs (13/498 or 3%) in controlled comparator clinical trials.Table 2: Summary of Serious Cardiovascular Events in Trials Comparing Repaglinide Tablets to Sulfonylureas (% of total patients with events)Repaglinide TabletsSU*Total Exposed1228498Serious CV Events4%3%Cardiac Ischemic Events2%2%Deaths due to CV Events0.5%0.4%*: glyburide and glipizideSeven controlled clinical trials included repaglinide tablet combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or repaglinide tablets plus metformin) (n=120). There were six serious adverse events of myocardial ischemia in patients treated with repaglinide tablets plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study [see Warnings and Precautions (5.3)].Combination Therapy with ThiazolidinedionesHypoglycemiaDuring 24-week treatment clinical trials of repaglinide tablets -rosiglitazone or repaglinide tablets -pioglitazone combination therapy (a total of 250 patients in combination therapy), hypoglycemia (blood glucose < 50 mg/dL) occurred in 7% of patients in combination therapy compared to 7% for repaglinide tablets monotherapy, and 2% for thiazolidinedione monotherapy.Peripheral Edema and Heart FailurePeripheral edema was reported in 12 out of 250 (4.8%) repaglinide tablets -thiazolidinedione combination therapy patients and 3 out of 124 (2.4%) thiazolidinedione monotherapy patients, with no cases reported in these trials for repaglinide tablets monotherapy. There were reports in 2 of 250 patients (0.8%) treated with repaglinide tablets -thiazolidinedione therapy of episodes of edema with congestive heart failure. Both patients had a prior history of coronary artery disease and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported.Weight GainMean weight increases associated with combination, repaglinide tablets and pioglitazone therapy were 5.5 kg, 0.3 kg, and 2.0 kg respectively. Mean weight increases associated with combination, repaglinide tablets and rosiglitazone therapy were 4.5 kg, 1.3 kg, and 3.3 kg respectively.Infrequent Adverse Events (<1% of Patients)Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, thrombocytopenia, leukopenia, and anaphylactoid reactions.

6.2 Postmarketing Experience

  • The following additional adverse reactions have been identified during post approval use of repaglinide tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or a causal relationship to drug exposure. •Alopecia •Hemolytic anemia •Pancreatitis •Stevens-Johnson Syndrome •Severe hepatic dysfunction including jaundice and hepatitis

7 Drug Interactions

Clinically Important Drug Interactions with Repaglinide TabletsTable 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with repaglinide tablets and instructions for preventing or managing them.Table 3: Clinically Important Drug Interactions with Repaglinide TabletsGemfibrozilClinical Impact:Gemfibrozil significantly increased repaglinide exposures by 8.1 fold [see Clinical Pharmacology (12.3)]Intervention:Do not administer repaglinide tablets to patients receiving gemfibrozil [see Contraindications (4)].ClopidogrelClinical Impact:Clopidogrel increased repaglinide exposures by 3.9-5.1 fold [see Clinical Pharmacology (12.3)]Intervention:Avoid concomitant use of repaglinide tablets with clopidogrel. If concomitant use can not be avoided, initiate repaglinide tablets at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg [see DOSAGE AND ADMINISTRATION (2.3)]. Increased frequency of glucose monitoring may be required during concomitant use.CyclosporineClinical Impact:Cyclosporine increased low dose repaglinide exposures by 2.5 fold [see Clinical Pharmacology (12.3)]Intervention:Daily maximum repaglinide tablets dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when repaglinide tablets is co-administered with cyclosporine.CYP2C8 and CYP3A4 InhibitorsIntervention:Repaglinide tablet dose reductions and increased frequency of glucose monitoring may be required when co-administered.Examples:Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin). Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.CYP2C8 and CYP3A4 InducersIntervention:Repaglinide tablet dose increases and increased frequency of glucose monitoring may be required when co-administeredExamples:Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapineDrugs That May Increase the Risk of HypoglycemiaIntervention:Repaglinide tablet dose reductions and increased frequency of glucose monitoring may be required when co-administered.Examples:Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibioticsDrugs That May Decrease the Blood Glucose Lowering Effect of Repaglinide TabletsIntervention:Repaglinide tablet dose increases and increased frequency of glucose monitoring may be required when co-administered.Examples:Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.Drugs That May Blunt Signs and Symptoms of HypoglycemiaIntervention:Increased frequency of glucose monitoring may be required when repaglinide tablets are co-administered with these drugs.Examples:beta-blockers, clonidine, guanethidine, and reserpine

8.1 Pregnancy

Pregnancy Category C.There are no adequate and well-controlled studies in pregnant women. It is unknown whether repaglinide tablets can cause fetal harm when administered to a pregnant woman. Repaglinide tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Repaglinide was not teratogenic in rats or rabbits at doses 40 times (rats) and approximately 0.8 times (rabbit) clinical exposure (on a mg/m2 basis) throughout pregnancy. Offspring of rat dams exposed to repaglinide at 15 times clinical exposure on a mg/m2 basis during days 17 to 22 of gestation and during lactation developed nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus during the postnatal period. This effect was not seen at doses up to 2.5 times clinical exposure (on a mg/m2 basis) on days 1 to 22 of pregnancy or at higher doses given during days 1 to 16 of pregnancy. Relevant human exposure has not occurred to date and therefore the safety of repaglinide tablet administration throughout pregnancy or lactation cannot be established.

8.3 Nursing Mothers

Although it is not known whether repaglinide is excreted in human milk some oral agents are known to be excreted by this route. Because the potential for hypoglycemia in nursing infants may exist, and because of the effects on nursing animals, a decision should be made as to whether repaglinide tablets should be discontinued in nursing mothers, or if mothers should discontinue nursing. If repaglinide tablets are discontinued and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered. In rat reproduction studies, measurable levels of repaglinide were detected in the breast milk of the dams and lowered blood glucose levels were observed in the pups. Cross fostering studies indicated that skeletal changes [see Use in Specific Populations (8.1)] could be induced in control pups nursed by treated dams, although this occurred to a lesser degree than those pups treated in utero.

8.4 Pediatric Use

Safety and effectiveness have not been established in pediatric patients.

8.5 Geriatric Use

In clinical studies of 24 weeks or greater duration, 415 patients were over 65 years of age and no patients were greater than 75 years of age. In one-year, active-controlled trials, no differences were seen in effectiveness or adverse events between these subjects and those less than 65. There was no increase in frequency or severity of hypoglycemia in older subjects, but greater sensitivity of some older individuals to repaglinide tablet therapy cannot be ruled out.

8.6 Renal Impairment

Pharmacokinetic studies of repaglinide were conducted in patients with mild to moderate renal function impairment (CrCl = 40 – 80 mL/min), and severe renal function impairment (CrCl = 20 – 40 mL/min). Initial dose adjustment is not required in patients with mild to moderate renal dysfunction. However, patients with severe renal function impairment should initiate repaglinide tablet therapy with the 0.5 mg dose and be carefully titrated [see Dosage and Administration (2.2)].Studies were not conducted in patients with creatinine clearances below 20 mL/min or patients with renal failure requiring hemodialysis.

8.7 Hepatic Impairment

A single-dose study was conducted 12 patients with chronic liver disease. Patients with moderate to severe impairment of liver function had higher and more prolonged serum concentrations. Therefore, repaglinide tablets should be used cautiously in patients with impaired liver function. Longer intervals between dose adjustments may be needed to allow full assessment of response.

10 Overdosage

Severe hypoglycemic reactions with coma, seizure, or other neurological impairment may occur and constitute medical emergencies requiring immediate hospitalization. Hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring may continue until the physician is assured that the patient is out of danger. Patients should be closely monitored for a minimum of 24 to 48 hours, since hypoglycemia may recur after apparent clinical recovery. There is no evidence that repaglinide tablets are dialyzable using hemodialysis.

11 Description

Repaglinide Tablets, USP are an oral blood glucose-lowering drug of the glinide class. Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues.Structural Formula of RepaglinideRepaglinide is a white to off-white powder with molecular formula C27H36N2O4 and a molecular weight of 452.6. Repaglinide Tablets, USP contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: anhydrous dibasic calcium phosphate, microcrystalline cellulose, corn starch, polacrilin potassium, povidone, glycerin, magnesium stearate, meglumine, and poloxamer, and colloidal silicon dioxide. The 1 mg and 2 mg tablets contain ferric oxides (yellow and red, respectively) as coloring agents.

12.1 Mechanism Of Action

Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.

12.2 Pharmacodynamics

  • A four-week, double-blind, placebo-controlled dose-response trial was conducted in 138 patients with type 2 diabetes using doses ranging from 0.25 (not an approved dose) to 4 mg taken with each of three meals. Repaglinide tablet therapy resulted in dose-proportional glucose lowering over the full dose range. Plasma insulin levels increased after meals and reverted toward baseline before the next meal. Most of the fasting blood glucose-lowering effect was demonstrated within 1-2 weeks.In a double-blind, placebo-controlled, 3-month dose titration study, repaglinide tablets or placebo doses for each patient were increased weekly from 0.25 mg (not an approved dose) through 0.5, 1, and 2 mg, to a maximum of 4 mg, until a fasting plasma glucose (FPG) level <160 mg/dL was achieved or the maximum dose reached. The dose that achieved the targeted control or the maximum dose was continued to end of study. FPG and 2-hour post-prandial glucose (PPG) increased in patients receiving placebo and decreased in patients treated with repaglinide. Differences between the repaglinide- and placebo-treated groups were -61 mg/dL (FPG) and -104 mg/dL (PPG) (Table 4).Table 4: Repaglinide Tablets vs Placebo:Mean Change from Baseline after 3 Months of TreatmentRepaglinidePlaceboN6633Fasting Plasma Glucose (mg/dL) Baseline220.2215.3 Change from baseline(at last visit)-31.0*30.3Post Prandial Glucose (mg/dL) Baseline261.7245.2 Change from baseline(at last visit)-47.6*56.5*: p< 0.05 for between group differenceThe dosing of repaglinide tablets relative to meal-related insulin release was studied in three trials including 58 patients. Glycemic control was maintained during a period in which the meal and dosing pattern was varied (2, 3 or 4 meals per day; before meals x 2, 3, or 4) compared with a period of 3 regular meals and 3 doses per day (before meals x 3). Blood glucose-lowering effect did not differ when repaglinide tablets were administered at the start of a meal, 15 minutes before, or 30 minutes before the meal.

12.3 Pharmacokinetics

  • The pharmacokinetic parameters of repaglinide obtained from a single-dose, crossover study in healthy subjects and from a multiple-dose, parallel, dose-proportionality (0.5, 1, 2 and 4 mg) study in patients with type 2 diabetes are summarized in Tables 5 and 6. These data indicate that repaglinide did not accumulate in serum. Clearance of oral repaglinide did not change over the 0.5 - 4 mg dose range, indicating a linear relationship between dose and plasma drug levels.Table 5: Pharmacokinetic Parameters for Repaglinide in Healthy SubjectsParameterCL (based on i.v.)38 ± 16 L/hrVss (based on i.v.)31 ± 12 LAbsBio56 ± 9%CL = total body clearanceVss = volume of distribution at steady stateAbsBio = absolute bioavailabilityTable 6: Pharmacokinetic Parameters for Repaglinide in Patients with Type 2 Diabetes*Pharmacokinetic ParameterDose(mg)AUC0-24 hr(ng/mL*hr)Mean (SD)Cmax0-5 hr(ng/mL)Mean (SD)0.568.9 (154.4)9.8 (10.2)1125.8 (129.8)18.3 (9.1)2152.4 (89.60)26.0 (13.0)4447.4 (211.3)65.8 (30.1)Tmax0-5 hrMeans (SD)T½Means (Ind Range)0.5 - 41.0 – 1.4 (0.3 – 0.5) hr1.0 – 1.4 (0.4 – 8.0) hr*dosed preprandially with three mealsAbsorptionAfter oral administration, repaglinide is completely absorbed from the gastrointestinal tract. After single and multiple oral doses in healthy subjects or in patients, peak plasma drug levels (Cmax ) occur within 1 hour (Tmax ). Repaglinide is eliminated from the blood stream with a half-life of approximately 1 hour. The mean absolute bioavailability is 56%. When repaglinide was given with food, the mean Tmax was not changed, but the mean Cmax and AUC (area under the time/plasma concentration curve) were decreased 20% and 12.4%, respectively.DistributionAfter intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (Vss) was 31 L, and the total body clearance (CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%.Metabolism and EliminationRepaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an IV or oral dose. The major metabolites are an oxidized dicarboxylic acid (M2), the aromatic amine (M1), and the acyl glucuronide (M7). The cytochrome P-450 enzyme system, specifically 2C8 and 3A4, have been shown to be involved in the N-dealkylation of repaglinide to M2 and the further oxidation to M1. Metabolites do not contribute to the glucose-lowering effect of repaglinide. Within 96 hours after dosing with 14C-repaglinide as a single, oral dose, approximately 90% of the radiolabel was recovered in the feces and approximately 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. The major metabolite (M2) accounted for 60% of the administered dose. Less than 2% of parent drug was recovered in feces. Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1).Variability of ExposureRepaglinide AUC after multiple doses of 0.25 to 4 mg with each meal varies over a wide range. The intra-individual and inter-individual coefficients of variation were 36% and 69%, respectively. AUC over the therapeutic dose range included 69 to 1005 ng/mL*hr, but AUC exposure up to 5417 ng/mL*hr was reached in dose escalation studies without apparent adverse consequences.Specific PopulationsGeriatricHealthy volunteers were treated with a regimen of 2 mg repaglinide tablets taken before each of 3 meals. There were no significant differences in repaglinide pharmacokinetics between the group of patients <65 years of age and a comparably sized group of patents ≥65 years of age [see Use in Specific Populations (8.5)].GenderA comparison of pharmacokinetics in males and females showed the AUC over the 0.5 mg to 4 mg dose range to be 15% to 70% higher in females with type 2 diabetes. This difference was not reflected in the frequency of hypoglycemic episodes (male: 16%; female: 17%) or other adverse events.RaceNo pharmacokinetic studies to assess the effects of race have been performed, but in a U.S. 1-year study in patients with type 2 diabetes, the blood glucose-lowering effect was comparable between Caucasians (n=297) and African-Americans (n=33). In a U.S. dose-response study, there was no apparent difference in exposure (AUC) between Caucasians (n=74) and Hispanics (n=33).Renal ImpairmentSingle-dose and steady-state pharmacokinetics of repaglinide were compared between patients with type 2 diabetes and normal renal function (CrCl > 80 mL/min), mild to moderate renal function impairment (CrCl = 40 – 80 mL/min), and severe renal function impairment (CrCl = 20 – 40 mL/min). Both AUC and Cmax of repaglinide were similar in patients with normal and mild to moderately impaired renal function (mean values 56.7 ng/mL*hr vs 57.2 ng/mL*hr and 37.5 ng/mL vs 37.7 ng/mL, respectively.) Patients with severely reduced renal function had elevated mean AUC and Cmax values (98.0 ng/mL*hr and 50.7 ng/mL, respectively), but this study showed only a weak correlation between repaglinide levels and creatinine clearance.Hepatic ImpairmentA single-dose, open-label study was conducted in 12 healthy subjects and 12 patients with chronic liver disease (CLD) classified by Child-Pugh scale and caffeine clearance. Patients with moderate to severe impairment of liver function had higher and more prolonged serum concentrations of both total and unbound repaglinide than healthy subjects (AUChealthy : 91.6 ng/mL*hr; AUCCLD patients : 368.9 ng/mL*hr; Cmax, healthy : 46.7 ng/mL; Cmax, CLD patients : 105.4 ng/mL). AUC was statistically correlated with caffeine clearance. No difference in glucose profiles was observed across patient groups.Drug-Drug InteractionsDrug interaction studies performed in healthy volunteers show that repaglinide tablets had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline, or warfarin. Co-administration of cimetidine with repaglinide tablets did not significantly alter the absorption and disposition of repaglinide.Additionally, the following drugs were studied in healthy volunteers with co-administration of repaglinide tablets.Table 7: Effect of Other Drugs on AUC and Cmax of RepaglinideStudy DrugDosing Repaglinide Dosing1RepaglinideAUCCmaxClarithromycin* 250 mg BIDfor 4 days 40% ↑ 67% ↑Clopidogrel* 300 mg  (Day 1)75 mg QD (Day 2-3)0.25 mg(Day 1 and 3) (day 1) 5.1 fold ↑(3.9-6.6)(day 3) 3.9 fold ↑(2.9-5.3) 2.5 fold ↑(1.8-3.5)2.0 fold ↑(1.3-3.1)Cyclosporine 100 mg(2 doses 12 hours apart) 2.5 fold ↑ 1.8 fold ↑Deferasirox* 30 mg/kg QDfor 4 days0.5 mg 2.3 fold ↑ 62% ↑Fenofibrate 200 mg QDfor 5 days 0% 0%Gemfibrozil* 600 mg BIDfor 3 days 8.1 fold ↑ 2.4 fold ↑Itraconazole* 100 mg BIDfor 3 days 1.4 fold ↑ 1.5 fold ↑Gemfibrozil + Itraconazole*Co-administration Gem: 600 mg BIDfor 3 daysItra: 100 mg BIDfor 3 days 19 fold ↑ 2.8 fold ↑Ketoconazole 200 mg QDfor 4 days2 mg 15% ↑ 16% ↑Levonorgestrel/ethinyl Estradiol (0.15 mg/0.03 mg)Combination tablet QDfor 21 days2 mg 0% 20% ↑Nifedipine* 10 mg TIDfor 4 days2 mg 0% 0%Rifampin* 600 mg QDfor 6-7 days4 mg 32 - 80% ↓ 17 - 79% ↓Simvastatin 20 mg QDfor 4 days2 mg 0% 26% ↑Trimethoprim* 160 mg BIDfor 2 days160 mg QDfor 1 day 61% ↑ 41% ↑1 Unless indicated all drug interactions were observed with single dose of 0.25 mg repaglinide↑ indicates increase↓ indicates decrease* Indicates data are from published literature

13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility

In a 104-week carcinogenicity study in rats at doses up to 120 mg/kg/day, which is approximately 60 times clinical exposure on a mg/m2 basis, the incidences of benign adenomas of the thyroid and liver were increased in male rats. No evidence of carcinogenicity was found in female rats. The higher incidences of thyroid and liver tumors in male rats were not seen at lower dose of 30 mg/kg/day and 60 mg/kg/day respectively (which are over 15 and 30 times, respectively, clinical exposures on a mg/m2 basis). In a 104-week carcinogenicity study in mice at doses up to 500 mg/kg/day, no evidence of carcinogenicity was found in mice (which is approximately 125 times clinical exposure on a mg/m2 basis).Repaglinide was non-genotoxic in a battery of in vivo and in vitro studies: Bacterial mutagenesis (Ames test), in vitro forward cell mutation assay in V79 cells (HGPRT), in vitro chromosomal aberration assay in human lymphocytes, unscheduled and replicating DNA synthesis in rat liver, and in vivo mouse and rat micronucleus tests.In a rat fertility study, repaglinide was administered to male and female rats at doses up to 300 and 80 mg/kg/day, respectively. No adverse effects on fertility were observed (which are over 40 times clinical exposure on a mg/m2 basis).

14.1 Monotherapy Trials

A double-blind, placebo-controlled trial was carried out in 362 patients treated for 24 weeks. HbA1c for the repaglinide- treated groups (1 and 4 mg groups combined) at the end of the study was decreased compared to the placebo-treated group in treatment naïve patients and in patients previously treated with oral hypoglycemic agents by 2.1% and 1.7%, respectively. In this fixed-dose trial, patients who were treatment naïve to oral hypoglycemic agent therapy and patients with a HbA1c below 8% at baseline showed greater blood glucose-lowering.

14.2 Combination Trials

  • Repaglinide Tablets in Combination With MetforminRepaglinide tablets were studied in combination with metformin in 83 patients not satisfactorily controlled on exercise, diet, and metformin alone. Repaglinide tablet dosage was titrated for 4 to 8 weeks, followed by a 3-month maintenance period. Combination therapy with repaglinide tablets and metformin resulted in statistically significant improvement in HbA1c and fasting plasma glucose (FPG) compared to repaglinide tablets or metformin monotherapy (Table 8). In this study where metformin dosage was kept constant, the combination therapy of repaglinide tablets and metformin showed dose-sparing effects with respect to repaglinide tablets. The improvement in HbA1c and FPG of the combination group was achieved at a lower daily repaglinide tablet dosage than in the repaglinide tablets monotherapy group (Table 8).Table 8: Repaglinide Tablets in Combination with Metformin:Mean Change from Baseline after 4 to 5 Months of Treatment1 Repaglinide TabletMonotherapy Repaglinide TabletCombination Therapywith Metformin MetforminMonotherapyN 28 27 27Median Final Dose (mg/day) 12 6 (Repaglinide Tablets)1500 (metformin) 1500HbA1c (%) Baseline 8.6 8.3 8.6 Change from baseline -0.38 -1.41* -0.33Fasting Plasma Glucose (mg/dL) Baseline 174 184 194 Change from baseline 8.8 -39.2* -4.5Weight (kg) Baseline 87 93 91 Change from baseline 3.0 2.4# -0.901: based on intent-to-treat analysis*: p< 0.05, for pairwise comparisons with repaglinide tablets and metformin monotherapy.#: p< 0.05, for pairwise comparison with metformin.Repaglinide Tablets in Combination With PioglitazoneA combination therapy regimen of repaglinide tablets and pioglitazone (N=123) was compared to repaglinide tablets alone (N=61) and pioglitazone alone (N=62) in a 24-week trial that enrolled 246 patients previously treated with sulfonylurea or metformin monotherapy (HbA1c > 7.0%). Repaglinide tablets dosage was titrated during the first 12 weeks, followed by a 12-week maintenance period. Combination therapy resulted in statistically significant improvement in HbA1c and FPG compared to monotherapy (Figure 1). The changes from baseline for completers in FPG (mg/dL) and HbA1c (%), respectively were: -39.8 mg/dL and -0.1% for repaglinide tablets, -35.3 mg/dL and -0.1% for pioglitazone and -92.4 mg/dL and -1.9% for the combination. In this study where pioglitazone dosage was kept constant, the combination therapy group showed dose-sparing effects with respect to repaglinide tablets (see Figure 1 Legend). The improvement in HbA1c and FPG of the combination group was achieved at a lower daily repaglinide tablet dosage than in the repaglinide tablet monotherapy group.Figure 1: Repaglinide Tablets in Combination with Pioglitazone: HbA1c ValuesLEGEND: HbA1c values by study week for patients who completed study (combination, N = 101; Repaglinide, N = 35, pioglitazone, N = 26).Subjects with FPG above 270 mg/dL were withdrawn from the study.Pioglitazone dose: fixed at 30 mg/day; repaglinide median final dose: 6 mg/day for combination and 10 mg/day for monotherapy.Repaglinide Tablets in Combination With RosiglitazoneA combination therapy regimen of repaglinide tablets and rosiglitazone was compared to monotherapy with either agent alone in a 24-week trial that enrolled 252 patients previously treated with sulfonylurea or metformin (HbA1c > 7.0%). Combination therapy resulted in statistically significant improvement in HbA1c and FPG compared to monotherapy (Table 9 below). The glycemic effects of the combination therapy were dose-sparing with respect to both total daily repaglinide tablet dosage and total daily rosiglitazone dosage (see Table 9 Legend). The improvement in HbA1c and FPG of the combination therapy group was achieved with lower daily dose of repaglinide tablets and rosiglitazone, as compared to the respective monotherapy groups.Table 9: Repaglinide Tablets in Combination with Rosiglitazone:Mean Change from Baseline in a 24-Week Study1 Repaglinide TabletMonotherapy Repaglinide TabletCombination Therapywith Rosiglitazone RosiglitazoneMonotherapyN 63 127 62Median Final Dose (mg/day) 12 6 (Repaglinide Tablets)4 (Rosiglitazone) 8HbA1c (%) Baseline 9.3 9.1 9.0 Change from baseline -0.17 -1.43* -0.56Fasting Plasma Glucose (mg/dL) Baseline 269 257 252 Change from baseline -54 -94* -67Change in Weight (kg) +1.3 +4.5# +3.31: based on intent-to-treat analysis*: p-value ≤ 0.001 for comparison to either monotherapy#: p-value < 0.001 for comparison to repaglinide tablets

16 How Supplied/Storage And Handling

  • Repaglinide Tablets, USP are supplied as round tablets with beveled edges on both sides available in 0.5 mg (white, debossed with “P240” on one side), 1 mg (yellow, debossed with “P241” on one side) and 2 mg (pink, debossed with “P242” on one side) strengths.  0.5 mg tablets (white) Bottles of 100 NDC 0574-0240-01 Bottles of 500 NDC 0574-0240-05 Bottles of 1000 NDC 0574-0240-10 1 mg tablets (yellow) Bottles of 100 NDC 0574-0241-01 Bottles of 500 NDC 0574-0241-05 Bottles of 1000 NDC 0574-0241-10 2 mg tablets (pink) Bottles of 100 NDC 0574-0242-01 Bottles of 500 NDC 0574-0242-05 Bottles of 1000 NDC 0574-0242-10Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].Protect from moisture. Keep bottles tightly closed.Dispense in tight containers with safety closures.

17 Patient Counseling Information

HypoglycemiaInform patients that repaglinide tablets can cause hypoglycemia and instruct patients and their caregivers on self-management procedures including glucose monitoring and management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended [see Warnings and Precautions (5.1)].AdministrationInstruct patients to take repaglinide tablets within 30 minutes before meals. Instruct patients to skip their dose of repaglinide tablets when a meal is skipped. [see Dosage and Administration (2)].Drug InteractionsDiscuss potential drug interactions with patients and inform them of potential drug-drug interactions with repaglinide tablets. [see Drug Interactions (7)].


Manufactured ByPerrigo®Minneapolis, MN 5542722036588Z400 RC J2Rev 05-17 A

* Please review the disclaimer below.